Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or

For decades, the management of patients with advanced prostate cancer has been hormonal therapy, known as androgen deprivation therapy, which is intended to lower testosterone levels. Further incremental progress in the treatment of men with metastatic hormone‐sensitive prostate cancer (mHSPC) has c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2019-06, Vol.125 (11), p.1777-1788
Hauptverfasser:	Barata, Pedro C., Sartor, A. Oliver
Format:	Artikel
Sprache:	eng
Schlagworte:	abiraterone Acetic acid Androgens Androstenes - therapeutic use Antineoplastic Agents - therapeutic use Castration clinical trials Combinatorial analysis Deprivation Developmental stages docetaxel Docetaxel - therapeutic use hormone sensitive Humans Male Metastases Metastasis metastatic prostate cancer oligometastatic disease Oncology Patients Positron emission Positron emission tomography Prognosis Prostate cancer prostate‐specific membrane antigen (PSMA) Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - secondary Testosterone Therapy Tracers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!